Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431565 | 0.95 | GSK3B (0.39) | TEKKDRSCN9APDE1APDE1B | |
| SCHEMBL25430936 | 0.83 | GSK3B (0.35) | PDE10A | |
| SCHEMBL25428450 | 0.77 | SCN9A (0.42) | SCN9APDE10AKCNH2 | |
| SCHEMBL30544047 | 0.77 | SCN9A (0.42) | SCN9APDE10AKCNH2 | |
| SCHEMBL25430011 | 0.74 | TTBK1 (0.41) | TEKKDRPDE10A | |
| SCHEMBL25431696 | 0.73 | GRM2 (0.38) | SCN9A | |
| SCHEMBL25427800 | 0.72 | SCN9A (0.39) | SCN9APDE10AKCNH2 | |
| SCHEMBL25429484 | 0.69 | SCN8A (0.43) | SCN8ASCN10ASCN9A | |
| SCHEMBL20394227 | 0.67 | PDE10A (0.58) | PDE10A | |
| SCHEMBL20394208 | 0.66 | PDE10A (0.49) | PDE10AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |